Switch acceptance and persistence of adalimumab biosimilars in IBD patients: a prospective observational study.

ABSTRACT:

Background

Prospective data about the acceptance and outcomes of switching from the adalimumab (ADA) reference product (RP) to multiple ADA biosimilars in inflammatory bowel disease (IBD) patients are lacking.

Objectives

To evaluate the acceptance rate of switching from the ADA RP to ADA biosimilars, identify factors associated with non-acceptance, assess persistence at 6 and 12 months, determine reasons for discontinuation, analyze changes in disease activity, and explore patient perceptions at 12 months.

Design

A prospective study was conducted at a French tertiary center between July 2020 and September 2021, including consecutive IBD outpatients treated with ADA RP for over 6 weeks.

Methods

Patients were offered a switch to five different ADA biosimilars, wi

SUBMITTER: D'Abbundo G 

PROVIDER: S-EPMC12035160 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature